GRIFOLS S A/S (GRFS) Given Average Recommendation of “Hold” by Analysts

Posted by Grant Hamersma on Feb 14th, 2019 // No Comments

GRIFOLS S A/S (NASDAQ:GRFS) has earned an average rating of “Hold” from the nine research firms that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $19.00.

A number of equities research analysts have recently commented on the company. Berenberg Bank cut GRIFOLS S A/S from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. BidaskClub cut GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Wednesday, January 30th. Morgan Stanley dropped their target price on GRIFOLS S A/S from $20.00 to $19.00 and set an “underweight” rating on the stock in a research report on Wednesday, January 2nd. Finally, Zacks Investment Research cut GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research report on Tuesday, December 25th.

Hedge funds have recently bought and sold shares of the stock. Advisors Asset Management Inc. boosted its holdings in GRIFOLS S A/S by 58.0% in the 4th quarter. Advisors Asset Management Inc. now owns 3,629 shares of the biotechnology company’s stock worth $67,000 after buying an additional 1,332 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in GRIFOLS S A/S by 45.3% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,770 shares of the biotechnology company’s stock worth $105,000 after buying an additional 1,799 shares during the last quarter. SG Americas Securities LLC acquired a new stake in GRIFOLS S A/S in the 4th quarter worth about $144,000. Quadrant Capital Group LLC boosted its holdings in GRIFOLS S A/S by 20.2% in the 4th quarter. Quadrant Capital Group LLC now owns 14,098 shares of the biotechnology company’s stock worth $252,000 after buying an additional 2,365 shares during the last quarter. Finally, Financial Gravity Companies Inc. acquired a new stake in GRIFOLS S A/S in the 4th quarter worth about $289,000. Institutional investors own 19.57% of the company’s stock.

NASDAQ:GRFS opened at $19.00 on Thursday. GRIFOLS S A/S has a 52 week low of $17.42 and a 52 week high of $24.97. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.07 and a current ratio of 2.78. The stock has a market cap of $12.65 billion, a PE ratio of 17.27, a price-to-earnings-growth ratio of 1.24 and a beta of 1.07.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.